Kybella (Deoxycholic Acid): The Complete Guide

Overview

Kybella is a synthetic formulation of deoxycholic acid, a bile acid naturally produced by the human body to aid in the absorption and breakdown of dietary fat. When injected directly into subcutaneous fat tissue, deoxycholic acid destroys adipocyte (fat cell) membranes on contact, causing the cells to lyse and die. The body then clears the cellular debris through its natural inflammatory and macrophage-mediated processes over a period of weeks (Rotunda & Kolodney, 2006).

The FDA approved Kybella in April 2015 based on the REFINE clinical trial program -- a series of Phase 3 randomized, double-blind, placebo-controlled studies involving over 2,600 patients. The pivotal trials (REFINE-1 and REFINE-2) demonstrated statistically significant improvement in submental fat reduction compared to placebo, as measured by both clinician-rated and patient-rated scales (Jones et al., 2016).

Kybella occupies a unique position in the aesthetic medicine landscape as a non-surgical, injectable fat reduction option. It falls between non-invasive treatments like CoolSculpting (cryolipolysis) and invasive surgical procedures like liposuction. While its results are permanent, the treatment involves significant side effects including dramatic swelling ("bullfrog chin"), bruising, pain, and the risk of marginal mandibular nerve injury. Kybella is FDA-approved only for submental fat -- all other body areas are considered off-label use.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

Deoxycholic acid is an endogenous secondary bile acid produced in the human gut by bacterial metabolism of primary bile acids. In the digestive system, it functions as a biological detergent -- emulsifying dietary fats to facilitate their absorption. Kybella harnesses this same detergent property in a concentrated, injectable form to destroy subcutaneous fat cells.

Cytolytic Mechanism

When deoxycholic acid is injected into subcutaneous adipose tissue, it acts as a non-selective membranolytic agent. The molecule inserts into the phospholipid bilayer of cell membranes, disrupting their structural integrity and causing rapid cell lysis. Adipocytes are particularly vulnerable because of their large size and thin cell membranes stretched around a single large lipid droplet (Rotunda & Kolodney, 2006).

The cytolytic process occurs in a well-characterized sequence:

1. Immediate membrane disruption (minutes to hours): Deoxycholic acid molecules integrate into adipocyte cell membranes, causing membrane pore formation and rapid cell lysis. Intracellular lipid contents are released into the surrounding interstitial space.
2. Inflammatory response (days 1-7): The released cellular debris and lipids trigger a robust localized inflammatory response. Neutrophils and macrophages are recruited to the treatment area. This inflammatory phase is responsible for the significant swelling and tenderness patients experience.
3. Phagocytic clearance (weeks 2-6): Macrophages engulf and process the lipid debris and cellular remnants. The cleared material is metabolized through normal hepatic pathways. Granulation tissue begins to form.
4. Tissue remodeling (weeks 6-12): Fibroblasts deposit new collagen in the treated area. The inflammatory infiltrate resolves. The net result is a reduction in adipose tissue volume with some degree of neocollagenesis and tissue tightening (Thuangtong et al., 2010).

Why Fat Reduction Is Permanent

Mature adipocytes (fat cells) are post-mitotic -- once destroyed, they do not regenerate. The number of fat cells in an adult is relatively fixed; weight gain occurs primarily through enlargement (hypertrophy) of existing cells, not creation of new ones. When Kybella destroys adipocytes in the submental area, those cells are permanently eliminated. This is the same biological principle underlying liposuction.

Important caveat: While the destroyed fat cells are gone permanently, significant weight gain can cause remaining fat cells in the treated area (and elsewhere) to enlarge. Patients who gain substantial weight after Kybella treatment may see some return of submental fullness, though typically less than before treatment.

Selectivity and Collateral Effect

Deoxycholic acid is not perfectly selective for adipocytes. At the concentrations used in Kybella (10 mg/mL), it can also damage other cell types in the immediate vicinity, including fibroblasts, endothelial cells, and muscle cells. This non-selectivity contributes to the significant local inflammatory response and is the mechanism behind nerve injury risk -- if the drug comes into contact with the marginal mandibular nerve branch, temporary neuropraxia can result (Humphrey et al., 2016).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

The REFINE Program: Pivotal Phase 3 Trials

The REFINE program consisted of three large, randomized, double-blind, placebo-controlled Phase 3 trials that formed the basis for FDA approval:

• REFINE-1 (NCT01294644): 506 patients randomized to Kybella or placebo. Patients received up to 6 treatment sessions at monthly intervals. The primary endpoint was a composite of clinician-rated submental fat reduction (CR-SMFRS) and patient-rated submental fat reduction (PR-SMFRS). Kybella demonstrated statistically significant superiority over placebo on both measures (Jones et al., 2016).
• REFINE-2 (NCT01299623): 507 patients. Design and endpoints mirrored REFINE-1. Results confirmed the findings with consistent efficacy and safety (Ascher et al., 2014).
• REFINE-3 (NCT01370746): Extension study evaluating long-term durability. Demonstrated that fat reduction achieved with Kybella was maintained without retreatment at follow-up beyond one year.

Pooled Efficacy Results

A pooled analysis of the REFINE trials involving over 1,600 patients demonstrated the following key outcomes (Dayan et al., 2016):

Patient Satisfaction Data

A dedicated analysis of patient-reported outcomes from the REFINE program demonstrated that treatment satisfaction was high and sustained. Patients reported improved self-perception related to their chin profile, with many describing meaningful improvement in self-consciousness about their submental area. By study end, 79% of Kybella-treated patients reported satisfaction with their chin appearance, compared to 33.8% of placebo-treated patients (Dover et al., 2017).

Mechanistic Research

Foundational work by Rotunda and Kolodney established that deoxycholic acid -- not phosphatidylcholine -- is the active cytolytic agent in fat-dissolving injections. Their research demonstrated that deoxycholic acid alone produced equivalent adipocyte lysis to the combination formulations used in "mesotherapy" protocols, while phosphatidylcholine alone had minimal lytic effect. This finding was pivotal in the development of Kybella as a pure deoxycholic acid formulation (Rotunda & Kolodney, 2006).

Comparative lipid dissolution studies confirmed that deoxycholic acid demonstrates dose-dependent and concentration-dependent adipocyte destruction, with a clear threshold concentration below which cellular lysis does not occur. This established the pharmacological rationale for the 10 mg/mL concentration used in the commercial product (Thuangtong et al., 2010).

Off-Label Body Contouring Research

Emerging research has investigated deoxycholic acid injections for fat reduction in areas beyond the submental region. A review of off-label uses examined applications in the jowls, bra fat, infragluteal fat, and knee fat pads. While early results showed some efficacy, these studies were small, uncontrolled, and the safety profile in non-submental areas is not as well characterized (Walker et al., 2021).

Limitations of the Research

• Submental area only: All pivotal trial data is limited to the submental area. Efficacy and safety in other body areas have not been established in Phase 3 trials.
• Subjective outcome measures: The primary endpoints (CR-SMFRS, PR-SMFRS) are grading scales, not volumetric measurements. Objective fat volume reduction data is limited.
• Comparison trials absent: No head-to-head trials comparing Kybella to CoolSculpting or liposuction have been conducted.
• Long-term data limited: While the REFINE-3 extension showed durability beyond one year, multi-year follow-up data on large cohorts is limited.
• Population homogeneity: Trial populations were predominantly Caucasian. Data in diverse skin types and body compositions is more limited.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA-Approved Indication

Kybella is FDA-approved for one indication: improvement in the appearance of moderate-to-severe convexity or fullness associated with submental fat in adults. It is the first and only FDA-approved injectable for this purpose. The approval was based on the REFINE Phase 3 clinical trial program demonstrating significant improvement over placebo (Jones et al., 2016).

Ideal Candidates

Kybella is best suited for patients who:

• Have moderate-to-severe submental fat (a visible "double chin") that bothers them
• Have good skin elasticity in the chin/neck area (skin needs to contract after fat removal)
• Are at or near their stable body weight
• Want a non-surgical alternative to liposuction
• Accept the downtime associated with significant post-treatment swelling
• Understand that multiple treatment sessions are needed

Who Is NOT a Good Candidate

• Significant skin laxity: Patients with loose, inelastic skin under the chin may experience worsened sagging after fat removal. These patients are often better served by surgical options (neck lift, liposuction with skin excision).
• Submental fullness caused by enlarged submandibular glands or platysmal banding: Kybella only addresses subcutaneous fat, not glandular enlargement or muscle-related fullness.
• Very large volume of submental fat: Patients with very large fat deposits may achieve insufficient results from Kybella alone and may be better candidates for liposuction.
• Active infection in the treatment area

Off-Label Uses

A 2021 review of off-label body applications concluded that while deoxycholic acid shows potential for small, localized fat deposits in non-submental areas, the evidence base is insufficient to recommend routine off-label use without further controlled trials (Walker et al., 2021).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

FDA-Approved Dosing Protocol

Source: Kybella FDA-approved prescribing information.

Administration Technique

The injection procedure follows a standardized protocol:

1. Patient assessment: The provider evaluates the submental fat pad, marks the treatment area, and identifies key anatomical landmarks -- particularly the marginal mandibular nerve to avoid injury.
2. Area marking: A grid pattern is marked on the submental area using 1 cm spacing. The treatment area is bounded by the hyoid bone inferiorly, the mandible superiorly, and the sternocleidomastoid muscles laterally.
3. Local anesthesia: Ice, topical numbing cream, or injectable lidocaine is typically used before treatment. Some providers also administer oral anxiolytics.
4. Injection: Using a 30-gauge needle, 0.2 mL of Kybella is injected subcutaneously at each grid point. Injections are placed into the fat layer -- not too superficial (skin necrosis risk) and not too deep (platysma muscle).
5. Post-treatment: Ice is applied. Patients are monitored briefly and given aftercare instructions.

Number of Sessions Required

Source: Ascher et al. (2014) — Phase 3 dosing protocol and safety.

Critical Safety Boundaries

• Avoid the marginal mandibular nerve: Injections must not be placed lateral to the platysma or near the mandibular border to minimize nerve injury risk.
• Correct tissue plane: Injections must be placed in the subcutaneous fat layer. Too superficial causes skin ulceration; too deep can affect the platysma muscle.
• Do not exceed maximum dose: No more than 10 mL (50 injections of 0.2 mL) per session. Exceeding this dose has not been studied and increases risk.
• Minimum interval: At least 1 month between sessions to allow adequate tissue healing and inflammatory resolution.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What to Expect

Typical Timeline per Treatment Session

Cumulative Results Across Sessions

Each treatment session produces additional fat reduction. The clinical trial data shows a dose-response relationship -- more treatment sessions correlate with greater improvement, up to a plateau typically reached after 4 sessions:

• After 1 session: Mild improvement. Some patients notice a difference; others may not see significant change after a single treatment.
• After 2 sessions: Most patients begin to see noticeable improvement in their chin profile. This is the point where the investment of time and discomfort begins to show visible returns.
• After 3-4 sessions: Optimal results for most patients. The pooled REFINE trial data showed that 70% of patients achieved at least a 1-grade improvement on the clinician-rated scale, and 79% reported satisfaction with their appearance (Dayan et al., 2016).
• After 5-6 sessions: Diminishing returns. Some patients with severe submental fullness benefit from additional sessions, but most achieve maximal improvement by session 4.

Permanence of Results

Results are permanent in the sense that destroyed fat cells do not regenerate. The REFINE-3 extension study confirmed that fat reduction was maintained without retreatment at follow-up beyond one year. However:

• Significant weight gain (10+ pounds) can expand remaining fat cells in the treated area, partially reversing the cosmetic effect
• Aging-related changes in skin laxity, muscle tone, and fat distribution continue independent of treatment
• The treatment does not prevent future weight gain from depositing fat in other areas

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Common Side Effects (Clinical Trial Data)

Incidence data from the pooled REFINE Phase 3 trials (Dayan et al., 2016).

Marginal Mandibular Nerve Injury

The most clinically significant adverse event is injury to the marginal mandibular branch of the facial nerve. This nerve controls the muscles of the lower lip and chin. When affected, patients develop:

• Asymmetric smile: Inability to fully depress the lower lip on the affected side, creating an uneven smile
• Difficulty with facial expressions: Particularly movements involving the lower face
• Incidence in clinical trials: Approximately 4% of Kybella-treated patients experienced marginal mandibular nerve injury
• Duration: In the vast majority of cases, this is temporary neuropraxia that resolves spontaneously within 1-6 weeks. Persistent injury beyond 6 months is rare but has been reported

Nerve injury risk is minimized by proper injection technique -- specifically, avoiding injections lateral to the treatment grid or near the mandibular border, and staying within the submental fat pad boundaries (Humphrey et al., 2016).

Rare but Serious Adverse Events

• Skin ulceration or necrosis: Reported in cases where injections were placed too superficially (intradermal rather than subcutaneous). Proper injection depth is critical.
• Dysphagia (difficulty swallowing): Reported in approximately 2% of patients. Typically mild and transient, related to swelling affecting the floor of the mouth. Resolves as swelling subsides.
• Alopecia at injection site: Rare reports of localized hair loss in the treatment area. Mechanism unclear; may relate to damage to hair follicles.
• Severe allergic reactions: Very rare. Standard precautions for injectable drug administration apply.

Contraindications

• Active infection at the treatment site
• Known hypersensitivity to deoxycholic acid
• Pregnancy and breastfeeding -- no safety data available
• Previous surgical alteration of the treatment area that may change the anatomical landmarks used for safe injection

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

Regulatory Approval Timeline

Prescription and Administration Requirements

Kybella is classified as a prescription medication in all approved markets. Important regulatory points:

• Provider requirements: Must be administered by a licensed healthcare provider. In the US, this typically includes physicians (MDs/DOs), nurse practitioners, and physician assistants -- depending on state scope-of-practice laws. Some states allow registered nurses to administer under physician supervision.
• Setting: Must be administered in a clinical setting with appropriate emergency equipment available.
• Training: Allergan offers a formal training program for providers. While not legally mandated, adequate training in facial anatomy and injection technique is the standard of care.
• Not available for self-administration: Unlike some injectables, Kybella is not dispensed to patients for self-use. Each treatment must be performed in a clinical setting.

Off-Label Regulation

Kybella's FDA approval is limited to submental fat. Any use in other body areas (jowls, bra fat, knee fat, etc.) is considered off-label. In the United States, licensed providers may legally prescribe FDA-approved drugs for off-label indications at their clinical discretion. However:

• Off-label use is not supported by Phase 3 clinical trial data
• The safety profile in non-submental areas is not as well characterized
• Informed consent should clearly communicate the off-label nature of the treatment
• Insurance will not cover off-label use (insurance rarely covers Kybella for any indication, as it is considered cosmetic)

Compounding and Generic Status

As of 2026, there is no FDA-approved generic version of Kybella. Deoxycholic acid is a known compound, but the specific pharmaceutical formulation, concentration, and purification required for injectable use is protected by Allergan's regulatory data. Compounding pharmacies may prepare deoxycholic acid formulations (sometimes referred to as PCDC -- phosphatidylcholine/deoxycholic acid combinations), but these are not FDA-approved products and may not be equivalent to Kybella in purity, concentration, or safety profile.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Insurance Coverage

Kybella is not covered by any health insurance plan. It is classified as a cosmetic procedure across all insurance categories. This applies to both the on-label indication (submental fat) and any off-label uses. All costs are entirely out-of-pocket, including:

• The product itself
• Provider fees for injection
• Any pre-treatment topical anesthetics or medications
• Follow-up visits (typically included in the treatment fee)

Cost Comparison: Submental Fat Reduction Options

Factors Affecting Cost

• Geographic location: Pricing is significantly higher in major metropolitan areas (New York, Los Angeles, Miami) compared to smaller markets.
• Provider type: Board-certified plastic surgeons and dermatologists may charge more than nurse practitioners or physician assistants.
• Number of vials per session: Each Kybella vial contains 2 mL (20 mg). Patients with larger treatment areas require more vials per session, increasing cost.
• Package deals: Some practices offer discounts for purchasing multiple sessions upfront.
• Allergan Alle rewards: Allergan's patient loyalty program (Alle, formerly Brilliant Distinctions) offers points/rebates on Kybella treatments, typically saving $50-$100 per treatment.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Q: Does Kybella actually work, or is it just swelling that makes it look different?

Answer: Kybella genuinely destroys fat cells. The REFINE Phase 3 trials used objective clinician-rated scales and MRI imaging in subset analyses to confirm actual reduction in submental fat volume -- not just perceptual change from swelling or tissue remodeling. The 70% clinician-rated improvement rate versus 18.6% for placebo confirms a real biological effect beyond placebo or swelling artifacts (Dayan et al., 2016). That said, some of the visual improvement may be augmented by neocollagenesis and mild skin tightening in the treated area.

Q: Is the swelling really that bad?

Answer: Yes. The swelling from Kybella is consistently described by patients and providers as more significant than most people expect, even with adequate counseling. Terms like "bullfrog chin" and "turkey gobbler" are commonly used to describe the appearance during the first 3-5 days. Most patients look visibly swollen and unusual for 5-7 days. Some degree of swelling can persist for 2-3 weeks. This is a physiological consequence of the cytolytic mechanism -- massive fat cell destruction triggers a proportional inflammatory response. Patients who are not prepared for this level of swelling have the highest rates of dissatisfaction.

Q: Is Kybella better than CoolSculpting for a double chin?

Answer: Neither is universally superior; the right choice depends on individual factors:

• Kybella advantages: More precise targeting, can treat smaller or irregular areas, may produce slightly more dramatic results per session, includes some skin tightening effect from inflammatory remodeling
• CoolSculpting advantages: Non-invasive (no needles), much less downtime, minimal pain, no nerve injury risk, no swelling of the same magnitude
• Kybella disadvantages: More painful, dramatic swelling, nerve injury risk, requires multiple office visits with significant downtime after each
• CoolSculpting disadvantages: Less predictable results, risk of paradoxical adipose hyperplasia (PAH), may not treat as small or precise an area

No head-to-head clinical trials comparing the two exist. Provider experience and patient anatomy often determine which is recommended.

Q: Can Kybella cause permanent nerve damage?

Answer: In the vast majority of cases, marginal mandibular nerve injury from Kybella is temporary -- resolving within 1-6 weeks as the nerve recovers from neuropraxia (functional impairment without structural damage). In the REFINE clinical trials, all reported cases of nerve injury resolved. However, rare cases of prolonged or persistent asymmetry beyond 6 months have been reported in post-marketing surveillance. The risk is minimized by proper injection technique and anatomical boundary adherence (Humphrey et al., 2016).

Q: If I gain weight after Kybella, will the double chin come back?

Answer: The destroyed fat cells are permanently gone. However, remaining fat cells in the treated area can enlarge (hypertrophy) with significant weight gain, and fat can also redistribute to other areas. Modest weight fluctuations (5-10 pounds) are unlikely to noticeably reverse results. Substantial weight gain (20+ pounds) may partially diminish the cosmetic improvement, though the treated area will typically remain smaller than it would have been without treatment at that same weight.

Q: Can I use Kybella for body fat -- stomach, love handles, thighs?

Answer: Kybella is FDA-approved only for submental fat. While deoxycholic acid can destroy fat cells anywhere it is injected, the safety and efficacy of Kybella in large body areas has not been established. The volumes of product needed for larger areas would far exceed the approved dosing limits, and the inflammatory response in larger treatment zones could be severe. Small focal deposits (jowls, bra fat, knee pads) have been treated off-label in limited case series, but this is not standard practice and carries uncalibrated risk (Walker et al., 2021).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• Kybella (deoxycholic acid) is the first and only FDA-approved injectable for the reduction of moderate-to-severe submental fat ("double chin"). It was approved in April 2015 based on the REFINE Phase 3 clinical trial program involving over 2,600 patients.
• The mechanism is cytolytic: deoxycholic acid physically destroys adipocyte cell membranes on contact. The body clears the debris through macrophage-mediated phagocytosis over weeks. Because mature fat cells do not regenerate, the results are permanent.
• Most patients require 2-4 treatment sessions, with up to 50 injections per session, spaced at least 1 month apart. The pooled clinical data shows 70% of patients achieved at least a 1-grade improvement, and 79% reported satisfaction with their appearance.
• Side effects are significant and expected. Swelling (87%), bruising (72%), pain (70%), and numbness (66%) are near-universal. The dramatic post-treatment swelling ("bullfrog chin") requires 5-7 days of social downtime per session. Patients must be thoroughly prepared.
• Marginal mandibular nerve injury occurs in approximately 4% of patients, causing temporary asymmetric smile. This typically resolves within weeks but is the most clinically significant risk.
• Kybella is FDA-approved only for submental fat. Off-label use in other body areas (jowls, bra fat, knees) has been reported but lacks Phase 3 data and carries less well-characterized risks.
• Cost ranges from $1,200-$1,800 per session, with total treatment cost of $2,400-$7,200. It is considered cosmetic and is not covered by insurance.
• Compared to alternatives: Kybella is more invasive than CoolSculpting but less invasive than liposuction. It occupies a middle ground with permanent results, significant downtime, and moderate cost.

Questions to Ask a Provider

• Am I a good candidate for Kybella, or would liposuction or CoolSculpting be more appropriate for my anatomy?
• How many sessions do you estimate I will need based on my submental fat volume?
• What is your experience level with Kybella, and how many patients have you treated?
• Have any of your patients experienced marginal mandibular nerve injury?
• Do I have adequate skin elasticity for the skin to contract after fat removal?
• What does the swelling typically look like, and can I see before/after photos including the swelling phase?
• What is the total estimated cost, including all sessions?
• What aftercare instructions should I follow?
• Do you offer any package pricing or participate in the Allergan Alle rewards program?
• What happens if I am not satisfied with the results after the recommended number of sessions?

Sources & Further Reading

Pivotal Clinical Trials (REFINE Program)

• Jones et al. (2016) -- "REFINE-1, a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial with ATX-101 for reduction of submental fat" -- Dermatologic Surgery
• Ascher et al. (2014) -- "Safety and efficacy of ATX-101 (deoxycholic acid injection) for reduction of submental fat: a phase 3 randomized controlled trial" -- JAMA Dermatology
• Dayan et al. (2016) -- "Pooled analysis of efficacy results from ATX-101 (deoxycholic acid injection) phase 3 clinical trials" -- Plastic and Reconstructive Surgery

Patient Outcomes & Satisfaction

• Dover et al. (2017) -- "Patient-reported outcomes from ATX-101 (deoxycholic acid injection) treatment: submental fat impact scale results" -- Dermatologic Surgery
• Humphrey et al. (2016) -- "Deoxycholic acid for reduction of submental fat: results and review of the literature" -- Dermatologic Surgery

Mechanism of Action

• Rotunda & Kolodney (2006) -- "Mesotherapy and phosphatidylcholine injections: historical clarification and review. The role of deoxycholic acid" -- Dermatologic Surgery
• Thuangtong et al. (2010) -- "Tissue-selective effects of injected deoxycholic acid vs. other surfactants" -- Dermatologic Surgery

Safety & Adverse Events

• Dayan et al. (2016) -- Pooled safety data from REFINE Phase 3 trials -- Plastic and Reconstructive Surgery
• Humphrey et al. (2016) -- Adverse event profile and nerve injury analysis -- Dermatologic Surgery
• Ascher et al. (2014) -- Phase 3 safety data including marginal mandibular nerve events -- JAMA Dermatology

Off-Label & Extended Applications

• Walker et al. (2021) -- "Off-label uses of injectable deoxycholic acid: a systematic review of body contouring applications" -- Journal of Cosmetic Dermatology

Comparative Treatments & Context

• Kilmer et al. (2014) -- "Safety and efficacy of cryolipolysis for non-invasive reduction of submental fat" -- Lasers in Surgery and Medicine
• Rzany et al. (2017) -- "Deoxycholic acid in aesthetic medicine: review of pharmacology and clinical use" -- Journal of Cosmetic and Laser Therapy
• Shridharani (2018) -- "Improvement in submental fat and skin laxity with ATX-101" -- Plastic and Reconstructive Surgery

Regulatory & Manufacturer Resources

• FDA: Press Announcement -- Kybella Approval (April 29, 2015)
• FDA: Kybella Prescribing Information (Full Label)

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.